We specialize in hard to find items
All Categories
Immune Checkpoint Inhibitors: Technology and Market Forecast
Share Tweet
*Price and Stocks may change without prior notice
*Packaging of actual item may differ from photo shown
- Electrical items MAY be 110 volts.
- 7 Day Return Policy
- All products are genuine and original
About Immune Checkpoint Inhibitors: Technology And Market
Global immune checkpoint inhibitors market reached over $23 billion in 2019, quite a growth giving the fact that the first product in this new class of therapeutics was launched just 9 years ago and the market was valued at $360 million in 2011. The market took off in 2015, the first full year on the market of Keytruda and Opdivo, the two PD-1 inhibitors from Merck and Bristol-Myers Squibb, respectively. US is the largest market, accounting for 62% of global revenue, the country has the highest penetration and the largest number of active users, which was estimated at 300,000 patients in 2019. Europe is a distant second with 18%, with Germany it's largest market. Japan currently accounts for 9% of the global market and China for 4%. However, China has a local industry that has managed to launch four PD-1 monoclonal antibody checkpoint inhibitors in 2019. Immune checkpoint inhibitors are tumor agnostic and represent some of the most advanced treatments available to patients with cancer. Their introduction has improved outcomes for patients with a wide range of solid tumors including: skin, lung, liver, kidney, stomach, breast, bladder, colon, head & neck, liver and cervical cancers. Immune checkpoint inhibitors are rapidly becoming the primary first-line treatments for patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic renal cell carcinoma. The movement to first-line treatment has occurred quickly, driven by significantly better outcomes in selected patients. There are currently over 3,000 clinical trials actively exploring the utility of new and existing checkpoint inhibitors in over 20 types of cancers, both as monotherapy and in combination with other cancer therapeutics. Despite accumulating evidence suggesting that only a fraction of cancer patients benefit from checkpoint inhibiting therapies, severe immune-related adverse events, and the need for predictive biomarkers, experts forecast the market to reach $40 billion by 2025. Immune Checkpoint Inhibitors – Technology and Market Forecast report offers a helicopter snapshot of current situation in this fast evolving dynamic market. The report is an insightful document targeted at senior executives in the pharmaceutical and biopharmaceutical industries. Strategists, brand, product, innovation, research, portfolio managers as well as venture capital professionals will find this report of particular value.
